|
|||
![]() |
|||
2016-12-01 08:05:14 CET 2016-12-01 08:05:14 CET Revenio Group Oyj - Managers' transactionsRevenio Group Corporation: Managers' transactionsRevenio Group Corporation: Managers' transactions December 1, 2016 at 09:05 Person subject to the notification requirement Name: Bocap Investment Oy Legal Person Position: Closely associated person Person discharging managerial responsibilities in issuer Name: Kakkonen, Kyösti Position: Member of the Board/Deputy member --------------------------------------------------------------------- Initial Notification Reference number: 743700I27E0FWSXLKK04_20161130130506_5 --------------------------------------------------------------------- Issuer Name: Revenio Group Oyj LEI: 743700I27E0FWSXLKK04 --------------------------------------------------------------------- Transaction details Transaction date: 2016-11-28 Venue: NASDAQ HELSINKI LTD (XHEL) Nature of the transaction: Disposal Instrument: Share ISIN: FI0009010912 Volume: 4800 Unit price: 25.49000 Euro Aggregated transactions Volume: 4800 Volume weighted average price: 25.49000 Euro For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932 DISTRIBUTION: Nasdaq Helsinki www.revenio.fi The Revenio Group in brief Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow- up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process. In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki. [] |
|||
|